About: Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma
Creator	Nishikawa, Hiroki Nakajima, Jun Arimoto, Akira Hatamaru, Keiichi Henmi, Shinichiro Inuzuka, Tadashi Ishikawa, Tetsuro Kimura, Toru Kita, Ryuichi Matsuda, Fumihiro Nasu, Akihiro Osaki, Yukio Saito, Sumio Sakamoto, Azusa Takeda, Haruhiko
topic	covid:c18255847a0b4f89e12a7fce7a0c731d43ff1850#this
source	PMC
abstract	BACKGROUND: The purpose of this investigation was to compare the outcome of percutaneous radiofrequency thermal ablation therapy (PRFA) with surgical resection (SR) in the treatment of single and small hepatocellular carcinoma (HCC). METHODS: We conducted a retrospective cohort study on 231 treatment naive patients with a single HCC ≤ 3 cm who had received either curative PRFA (162 patients) or curative SR (69 patients). All patients were regularly followed up after treatment at our department with blood and radiologic tests. RESULTS: The 1-, 3- and 5-year overall survival rates after PRFA and SR were 95.4%, 79.6% and 63.1%, respectively in the PRFA group and 100%, 81.4% and 74.6%, respectively in the SR group. The corresponding recurrence free survival rates at 1, 3 and 5 years after PRFA and SR were 82.0%, 38.3% and 18.0%, respectively in the PRFA group and 86.0%, 47.2% and 26.0%, respectively in the SR group. In terms of overall survival and recurrence free survival, there were no significant differences between these two groups. In comparison of PRFA group patients with liver cirrhosis (LC) (n = 127) and SR group patients with LC (n = 50) and in comparison of PRFA group patients without LC (n = 35) and SR group patients without LC (n = 19), there were also no significant differences between two groups in terms of overall survival and recurrence free survival. In the multivariate analysis of the risk factors contributing to overall survival, serum albumin level was the sole significant factor. In the multivariate analysis of the risk factors contributing to recurrence free survival, presence of LC was the sole significant factor. The rate of serious adverse events in the SR group was significantly higher than that in the PRFA group (P = 0.023). Hospitalization length in the SR group was significantly longer than in the PRFA group (P = 0.013). CONCLUSIONS: PRFA is as effective as SR in the treatment of single and small HCC, and is less invasive than SR. Therefore, PRFA could be a first choice for the treatment of single and small HCC.
has issue date	2011-12-28(xsd:dateTime)
bibo:doi	10.1186/1471-230x-11-143
bibo:pmid	22204311
has license	cc-by
sha1sum (hex)	c18255847a0b4f89e12a7fce7a0c731d43ff1850
schema:url	https://doi.org/10.1186/1471-230x-11-143
resource representing a document's title	Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma
has PubMed Central identifier	PMC3260104
has PubMed identifier	22204311
schema:publication	BMC Gastroenterol
resource representing a document's body	covid:c18255847a0b4f89e12a7fce7a0c731d43ff1850#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/c18255847a0b4f89e12a7fce7a0c731d43ff1850
is schema:about of	named entity 'higher' named entity 'group' named entity 'patients' named entity 'patients' named entity 'surgical resection' named entity 'GROUP' named entity 'INVESTIGATION' named entity 'YEARS' named entity 'RISK FACTORS' named entity 'CHOICE' named entity 'AFTER TREATMENT' named entity 'DEPARTMENT' named entity 'group' named entity 'percutaneous' named entity 'survival' named entity 'HCC' named entity 'naive' named entity 'regularly' named entity 'conducted' named entity 'multivariate analysis' named entity 'risk factors' named entity 'HCC' named entity 'liver cirrhosis' named entity 'significant factor' named entity 'survival rates' named entity 'hepatocellular carcinoma' named entity 'surgical resection' named entity 'thermal ablation' named entity 'radiofrequency' named entity 'percutaneous' named entity 'informed consent' named entity 'log-rank test' named entity 'Surgical resection' named entity 'multivariate analyses' named entity 'hepatic' named entity 'anatomy' named entity 'survival rate' named entity 'treatment groups' named entity 'liver disease' named entity 'Partial hepatectomy' named entity 'liver function' named entity 'HCC' named entity 'health problem' named entity 'surgical resection' named entity 'contrast material' named entity 'tumor markers' named entity 'chronic hepatitis B' named entity 'tumor progression' named entity 'gold standard therapy' named entity 'tumor' named entity 'ablation' named entity 'survival rate' named entity '2, 3' named entity 'tumors' named entity 'obesity' named entity 'platelet count' named entity 'CT scans' named entity 'Liver Diseases' named entity 'HCC' named entity 'log-rank test' named entity 'informed consent' named entity 'blood tests' named entity 'hilar' named entity 'medical condition' named entity 'survival rates'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software